`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`ARGENTUM PHARMACEUTICALS LLC, MYLAN
`PHARMACEUTICALS INC., BRECKENRIDGE PHARMACEUTICAL,
`INC., and ALEMBIC PHARMACEUTICALS, LTD.,
`Petitioners,
`
`v.
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.
`Patent Owner
`
`_______________
`
`Case IPR2016-002041
`Patent RE38,551 E
`_______________
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`1 Case IPR2016-01101, Case IPR2016-01242, and Case IPR2016-01245
`have been joined with this proceeding.
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`
`Exhibit Name
`
`U.S. Patent No. RE38,551
`Declaration of Dr. Binghe Wang
`Declaration of Dr. Clayton Heathcock from IPR2014-01126
`Joint Statement of Uncontested Facts
`U.S. Patent No. 5,773,475
`Excerpt from U.S. Patent Application No. 08/818,688
`District Court Claim Construction Opinion
`Philippe LeGall, 2-Substituted-2-acetamido-N-benzylacetamides.
`Synthesis, Spectroscopic and Anticonvulsant Properties (Dec. 1987)
`
`Petitioner’s
`Ex. No.
`1001
`1002
`1003
`1004
`1005
`1006
`1007
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`1013
`
`1014
`
`U.S. Patent No. 5,378,729
`
`Choi et al., Trimethylsilyl Halides: Effective Reagents for the
`Synthesis of β-Halo Amino Acid Derivatives, Tet. Lett., Vol. 36(39),
`pg. 7011 (1995)
`
`Purdie et al., The Alkylation of Sugars, J.A.C.S. Vol. 83, pg.
`1021 (1903)
`Kohn et al., Preparation and Anticonvulsant Activity of a Series of
`Functionalized α-Heteroatom-Substituted Amino Acids, J. Med.
`Chem. Vol. 34, pg. 2444 (1991)
`
`Silverman, R. B., The Organic Chemistry of Drug Design and Drug
`Action, Academic Press (1992)
`Development of New Stereoisomeric Drugs, U.S. F.D.A., May 1,
`1992
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`1020
`1021
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`1027
`1028
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Cortes et al., Effect of Structural Modification of the Hydantoin Ring
`on Anticonvulsant Activity, J. Med. Chem., Vol. 28, pg. 601 (1985)
`
`LeGall et al., Synthesis of Functionalized Non-Natural Amino Acid
`Derivatives via Amidoalkylation Transformations, Int. J. Peptide
`Protein Res. Vol. 32, pg. 279 (1988)
`
`Kohn et al., Synthesis and Anticonvulsant Activities of α-Heterocyclic
`α-Acetamido-N-benzylacetamide Derivatives, J. Med. Chem. Vol. 36,
`pg. 3350 (1993)
`
`Kohn et al., Preparation and Anticonvulsant Activity of a Series of
`Functionalized α-Aromatic and α-Heteroaromatic Amino Acids, J.
`Med. Chem. Vol. 33, pg. 919 (1990)
`
`U.S. Patent No. 5,654,301
`Patent Term Extension Request in U.S. Patent No. 5,654,301
`FDA Guideline for Industry, November 1994
`Schmidt, R., Dose-Finding Studies in Clinical Drug Development,
`Eur. J. Clin. Pharmacol, Vol. 34, pg. 15 (1988)
`Isbell, H. S., The Optical Rotation of the Various Asymmetric Carbon
`Atoms in the Hexose and Pentose Sugars, B. S. Jour. Research, Vol.
`5, pg. 1041 (1929)
`
`Wilson and Gisvold’s Textbook of Organic Medicinal Chemistry,
`Physicochemical Properties in Relation to Biologic Action, (Delgado
`J. N. & Remers W. A., eds. 1991)
`
`Thornber, C. W., Isosterism and Molecular Modification in Drug
`Design, Chem. Soc. Rev., Vol. 8(4) (1979)
`Reissue Declaration in Reissue of U.S. Patent No. 5,773,475
`Subpoena directed to The University of Houston
`Texas Public Information Act Requests and Responses
`3
`
`
`
`
`
`
`
`1029
`
`1030
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`1037
`1038
`
`1039
`
`1040
`1041
`1042
`1043
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Zhou et al., Decisions under Uncertainty: the Fuzzy Compromise
`Decision Support Problem, Eng. Opt. Vol. 20, pg. 21 (1992)
`Mistree et al., A Decision-Based Perspective for the Design
`of Methods for Systems Design, (1989)
`Mistree et al., A Decision-based Approach to Concurrent Design,
`Concurrent Engineering: Contemporary Issues and Modern Design
`Tools, (Parsaei, H. R. & Sullivan W. G. Eds. 1993)
`
`Ingram W. T., Concerning Periodic Points in Mappings of Continua,
`J. Am. Math. Soc., Vol. 104(2) (1988)
`Mattson, Current Challenges in the Treatment of Epilepsy,
`Neurology, Vol. 44(suppl. 5), pg. 84 (1994)
`Löscher et al., New Avenues for Anti-Epileptic Drug Discovery and
`Development, Nature Reviews: Drug Discovery, Vol. 12, pg. 12
`(2013)
`
`Cohen authorized amendment in U.S. Patent Application No.
`08/818,688
`Substitute Petition
`Marked-up Petition
`December 22, 2015 Email from M. Dowd to A. Reister, J. Robbins,
`and R. Longton.
`January 4, 2016 Email from M. Dowd to A. Reister, J. Robbins, and
`R. Longton.
`February 19, 2016 Email from M. Dowd to A. Reister.
`February 25, 2016 Letter from M. Dowd to A. Reister.
`February 25, 2016 Letter from M. Dowd to A. Reister.
`March 18, 2016 Email from M. Dowd to A. Reister.
`
`4
`
`
`
`
`
`
`
`1044
`
`1045
`1046
`1047
`1048
`1049
`1050
`1051
`
`1052
`
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`1058
`
`1059
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Docket for UCB Inc. et al v. Accord Healthcare Inc. et al, Case No.
`1:13-cv-01206-LPS (Dist. Del.).
`Petitioner’s Request for Ex Parte Reexam
`Ex Parte Reexamination Interview Summary
`Grant of Reexamination
`Transcript, Deposition of Dr. Carl Bazil (October 10, 2016)
`Transcript, Deposition of Dr. Christopher Vellturo (October 14, 2016)
`Transcript, Deposition of Dr. William Roush (October 21, 2016)
`Keppra Vimpat Brivaracetam, 2012 Epilepsy Pipeline Update
`Conference, San Francisco, February 2012
`The Merck Veterinary Manual, Principles of Therapy of Neurological
`Disease, Seizure Control (Thomas Schubert)
`Charalambous M et al., Antiepileptic Drugs’ Tolerability and Safety-A
`Systematic Review and Meta-Analysis of Adverse Effects in Dogs,
`BMC Veterinary Research, Vol. 12(79) (2016).
`Packer RMA, et al., Clinical Risk Factors Associated with Anti-
`Epileptic Drug Responsiveness in Canine Epilepsy, PLoS ONE, Vol.
`9(8) (2014)
`Packer RMA, et al., Assessment into the Usage of Levetiracetam in a
`Canine Epilepsy Clinic, BMC Veterinary Research, Vol. 11(25)
`(2015)
`Bhatti S et al., International Veterinary Epilepsy Task Force
`Consensus Proposal: Diagnostic Approach to Epilepsy in Dogs, BMC
`Veterinary Research, Vol. 11(148) (2015)
`Landmark J., Antiepileptic Drugs in Non-Epilepsy Disorders:
`Relations Between Mechanisms of Action and Clinical Efficacy, CNS
`Drugs, Vol. 22(1) (2008)
`Aneja S. & Sharma S., Newer Anti-epileptic Drugs, J. Indian
`Pediatrics, Vol. 50, pg. 1033 (2013)
`Bazil CW, New Antiepileptic Drugs, Curr. Neurol. Neurosci. Rep.,
`Vol. 1(4), pg. 369 (2001)
`
`5
`
`
`
`
`
`
`
`1060
`
`1061
`
`1062
`
`1063
`
`1064
`
`1065
`
`1066
`
`1067
`
`1068
`
`1069
`
`1070
`
`1071
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Bazil CW, Anticonvulsant Drug or Neuromodulator? The Growing
`Case for Anticonvulsant Uses Beyond Epilepsy, Curr. Neurol.
`Neurosci. Rep., Vol. 4, pg. 305 (2004)
`Zaccara G., The Adverse Event Profile of Lacosamide: A Systematic
`Review and Meta-Analysis of Randomized Controlled Trials,
`Epilepsia, Vol. 54(1) (2012)
`Sawh SC et al., Lacosamide Adjunctive Therapy for Partial-Onset
`Seizures: A Meta-Analysis, Peer J. (2013)
`Yasiry Z. & Shorvon S., The Relative Effectiveness of Five
`Antiepileptic Drugs in Treatment of Benzodiazepine-Resistant
`Convulsive Status Epilepticus: A Meta-Analysis of Published Studies,
`Seizure, Vol. 23(3), pg. 167 (2014)
`Wheless JW & Vazquez B., Rufinamide: A Novel Broad-Spectrum
`Antiepileptic Drug, Epilepsy Currents, Vol. 10(1) (2009)
`Trinka E. et al., Pharmacotherapy for Status Epilepticus, Drugs, Vol.
`75(13), pg. 1499 (2015).
`Glauser T. et al., Evidence-Based Guideline: Treatment of Convulsive
`Status Epilepticus in Children and Adults: Report of the Guideline
`Committee of the American Epilepsy Society, Epilepsy Currents, Vol.
`16, pg. 48 (2016)
`Proposed Algorithm for Convulsive Status Epilepticus, “Treatment of
`Convulsive Status Epilepticus in Children and Adults,” Epilepsy
`Currents, Vol. 16 (2016)
`Manno EM, Status Epilepticus: Current Treatment Strategies,
`Neurohospitalist, Vol. 1, pg. 23 (2011)
`French JA et al., Development of New Treatment Approaches for
`Epilepsy: Unmet Needs and Opportunities, Epilepsia, Vol. 54, sup. 4,
`pg. 3 (2013).
`Shrestha P. et al., Lacosamide-Induced Tactile Hallucinations in a
`Patient with Complex Partial Seizures, J. Neuropsychiatry and
`Clinical Neurosciences, Vol. 26, pg. E8 (2014).
`Simko J. et al., The Effect of Lacosamide on Bone Tissue in
`Orchidectomised Male Albino Wistar Rats, Biomed. Pap. Med. Fac.
`Univ. Palacky Olomouc Czech. Repub., Vol. 159(3), pg. 394 (2015)
`
`6
`
`
`
`
`
`
`
`1072
`
`1073
`
`1074
`
`1075
`
`1076
`
`1077
`
`1078
`
`1079
`
`1080
`
`1081
`
`1082
`
`1083
`
`1084
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Hilgers A & Schaefer M, Systematic Adverse Drug Reaction
`Monitoring of Patients Under Newer Antiepileptic Drugs Using
`Routine Clinical Data of Inpatients, Drugs Real World Outcome, Vol.
`3(2), pg. 209 (2016)
`Mancano, M, Recurrent Small Intestinal Ileus Due to Valsartan;
`Compulsive Behaviors Related to Rasagiline Use; Lacosamide-
`Induced Acute Pancreatitis; Brief Psychotic Disorder After Abrupt
`Withdrawal of Hydroxyzine; Hydroxyurea-Associated Acral
`Erythema; Penicillamine-Induced Degenerative Dermatosis, Hosp.
`Pharm., Vol. 49(1), pg. 902 (2014)
`Uthman BM et al., Long-Term Add-On Pregabalin Treatment in
`Patients with Partial-Onset Epilepsy: Pooled Analysis of Open-Label
`Clinical Trials, Epilepsia, Vol. 51(6), pg. 968 (2010).
`Damien Garde, UCB Inches Toward the FDA with its Latest Epilepsy
`Contender, FierceBiotech.com, July 23, 2014
`BRIVIACT® now available in U.S. pharmacies for epilepsy patients
`living with partial-onset seizures, UCB.com, May 31, 2016
`French J. & Gazzola D., New Generation Antiepileptic Drugs: What
`Do They Offer in Terms of Improved Tolerability and Safety?, Ther.
`Adv. Drug Saf., Vol. 2(4), pg. 141 (2011)
`Döring J. et al., Thirty Years of Orphan Drug Legislation and the
`Development of Drugs to Treat Rare Seizure Conditions: A Cross
`Sectional Analysis, pLoS One, Vol. 11(8) (2016)
`Goldenberg M., Overview of Drugs Used for Epilepsy and Seizures,
`PT, Vol. 35(7), pg. 392 (2010).
`UCB Heralds Successor to Keppra as EU Approves Vimpat for
`Epilepsy, ihs.com, Sep. 3, 2008
`Document marked as Exhibit 1 during Dr. Roush’s Deposition dated
`October 21, 2016
`Document marked as Exhibit 2 during Dr. Roush’s Deposition dated
`October 21, 2016
`Document marked as Exhibit 3 during Dr. Roush’s Deposition dated
`October 21, 2016
`Second Declaration of Dr. Binghe Wang
`7
`
`
`
`
`
`
`
`1085
`
`1086
`1087
`1088
`1089
`1090
`
`1091
`
`1092
`
`1093
`
`1094
`1095
`1096
`1097
`
`1098
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`CAS REGISTRY and CAS Registry Number FAQs, CAS A Division
`of the American Chemical Society,
`http://www.cas.org/content/chemical-substances/faqs
`Declaration of Dr. Deforest McDuff
`Declaration of Dr. Kathryn Davis
`Curriculum Vitae of Dr. Deforest McDuff
`Curriculum Vitae of Dr. Kathryn Davis
`Hirsch LJ et al., Cross-Sensitivity of Skin Rashes with Antiepileptic
`Drug Use, Neurology, Vol. 71(19), pg. 1527 (2008)
`Davis K, Guideline for Treatment of Status Epilepticus in Adults
`
`Rowan A.J. et al., New Onset Geriatric Epilepsy: A Randomized Study
`of Gabapentin, Lamotrigine, and Carbamazepine, Neurology, Vol.
`64(11), pg. 1868 (2005)
`Biton V et al., Safety and Tolerability of Lacosamide as Adjunctive
`Therapy for Adults with Partial-Onset Seizures: Analysis of Data
`Pooled from Three Randomized, Double-Blind, Placebo-Controlled
`Clinical Trials, Epilepsy & Behavior, Vol. 52, pg. 119 (2015)
`U.S. Patent No. 4,837,223
`U.S. Patent No. 4,943,639
`U.S. Patent No. 5,447,952
`Löscher W & Hönack D, Profile of UCB L059, A Novel
`Anticonvulsant Drug, In Models of Partial and Generalized Epilepsy
`in Mice and Rats, Eur. J. Pharmacol., Vol. 232, pg. 147 (1993)
`Gower A et al., UCB L059, A Novel Anti-Convulsant Drug:
`Pharmacological Profile in Animals, Eur. J. Pharmacol., Vol. 222, pg.
`193 (1992)
`
`8
`
`
`
`
`
`
`
`1099
`
`1100
`
`1101
`
`1102
`
`1103
`
`1104
`
`1105
`
`1106
`
`1107
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Vermeij TAC & Edelbroek PM, High-Performance Liquid
`Chromatographic and Megabore Gas—Liquid Chromatographic
`Determination of Levetiracetam (UCB L059) In Human Serum After
`Solid Phase Extraction, J. Chromatography B: Biomedical Sciences
`and Applications, Vol. 662(1), pg. 134 (1994)
`Wülfert E et al., Facilitation of Calcium-Dependent Cholinergic
`Function by UCB L059, a New “Second Generation” Nootropic
`Agent, Psychopharmacology Bulletin, Vol. 25(3), pg. 498 (1989)
`Ratnaraj N et al., A Micromethod for the Determination of the New
`Antiepileptic Drug Levetiracetam (UCB L059) In Serum or Plasma by
`High Performance Liquid Chromatography, Therapeutic Drug
`Monitoring, Vol. 18(2), pg. 154 (1996)
`Patsalos P & Duncan J, New Antiepileptic Drugs: A Review of Their
`Current Status and Clinical Potential, CNS Drugs, Vol. 2(1), pg. 40
`(1994)
`Ratnaraj N et al., Kinetics of Levetiracetam in Rat-Blood and
`Cerebrospinal-Fluid, Epilepsia, Vol. 36(Suppl. 3), pg. S38 (1995).
`
`Summary of the Protective Indices of all FAA compounds in Dr.
`Kohn’s References
`
`De Deyn PP et al., Assessment of the Safety of Orally Administered
`UCB L059 as Add-On Therapy in Patients Treated with Antiepileptic
`Drugs, Seizures, Vol. 1(Suppl. A) (1992)
`
`Singh P et al., A Pilot Study of the Efficacy and Tolerability of L059 in
`Patients with Refractory Epilepsy, Seizure, Vol. 1(Suppl. A) (1992)
`Types of Seizures, Epilepsy Foundation,
`http://www.epilepsy.com/learn/types-seizures
`
`9
`
`
`
`
`
`
`
`1108
`
`1109
`
`1110
`
`1111
`
`1112
`
`1113
`
`1114
`
`1115
`
`1116
`
`Types of Epilepsy Syndromes, Epilepsy Foundation,
`http://www.epilepsy.com/learn/types-epilepsy-syndromes
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`
`Döring JH et al., Thirty Years of Orphan Drug Legislation and the
`Development of Drugs to Treat Rare Seizures Conditions: A Cross
`Sectional Analysis, PLoS One, Vol. 11(8) (2016)
`
`Infantile Spasms/ West’s Syndrome, Epilepsy Foundation,
`http://www.epilepsy.com/learn/types-epilepsy-syndromes/infantile-
`spasms-wests-syndrome
`
`Lennox-Gastaut Syndrome (LGS), Epilepsy Foundation,
`http://www.epilepsy.com/learn/types-epilepsy-syndromes/lennox-
`gastaut-syndrome-lgs
`
`Dravet Syndrome, Epilepsy Foundation,
`http://www.epilepsy.com/learn/types-epilepsy-syndromes/dravet-
`syndrome
`
`Seizures in Newborns, Epilepsy Foundation,
`http://www.epilepsy.com/learn/seizures-youth/about-newborns-and-
`infants/seizures-newborns
`
`Pyridoxine-Dependent Epilepsy, NORD: National Organization for
`Rare Disorders, https://rarediseases.org/rare-diseases/pyridoxine-
`dependent-epilepsy/
`
`Nadkarni S & Devinsky O, Psychotropic Effects of Antiepileptic
`Drugs, Epilepsy Curr., Vol. 5(5), pg. 176 (2005)
`Ng F et al., The Role of Lamotrigine in the Management of Bipolar
`Disorder, Neuropsychiatr. Dis. Treat., Vol. 3(4), pg. 463 (2007)
`
`1
`
`
`
`
`
`
`
`
`
`1117
`
`1118
`
`1119
`
`1120
`
`1121
`
`1122
`
`1123
`
`1124
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Anticonvulsant (Antiepileptic Drugs), American Chronic Pain
`Association, https://www.theacpa.org/treatment/anticonvulsant-
`antiepileptic-drugs
`
`Seizure Medications and Pregnancy, Epilepsy Foundation,
`http://www.epilepsy.com/learn/treating-seizures-and-epilepsy/seizure-
`and-epilepsy-medicines/seizure-medications-and-0
`
`Hill D et al., Teratogenic Effects of Antiepileptic Drugs, Expert Rev.
`Neurother., Vol. 10(6), pg. 943 (2010)
`
`The North American AED (Antiepileptic Drug) Pregnancy Registry
`History, http://www.aedpregnancyregistry.org/about-history/
`
`North American AED Pregnancy Registry, Epilepsy Foundation,
`http://www.epilepsy.com/learn/treating-seizures-and-epilepsy/seizure-
`and-epilepsy-medicines/seizure-medications-and
`
`Update on Monotherapy Findings: Comparative Safety of 11
`Antiepileptic Drugs Used During Pregnancy, The North American
`Antiepileptic Drug Pregnancy Registry, Fall 2014 Newsletter,
`http://www.aedpregnancyregistry.org/wp-
`content/uploads/newsletter_fall_2014.pdf
`Swanborough, N, Lamotrigine Does Not Significantly Increase Risk of
`Birth Defects During Pregnancy, Says New Study, epilepsy society,
`April 8, 2016
`
`Safety and Efficacy of Lacosamide as Additional Therapy in Patients
`Suffering From Epileptic Tonic Clonic Seizures (VALUE), UCB
`Biosciences, Inc., https://clinicaltrials.gov/ct2/show/NCT02408549,
`Received March 31, 2015
`
`1
`
`
`
`
`
`
`
`
`
`1125
`
`1126
`
`1127
`
`1128
`
`1129
`
`1130
`
`1131
`
`1132
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Surges R et al., Is Levetiracetam Different From Other Antiepileptic
`Drugs? Levetiracetam and its Cellular Mechanism of Action in
`Epilepsy Revisited, Therapeutic Advances in Neurological Disorders,
`Vol. 1(1), pg. 13 (2008)
`Lynch B et al., The Synaptic Vesicle Protein SV2A is the Binding Site
`for the Antiepileptic Drug Levetiracetam, PNAS, Vol. 101(26), pg.
`9861 (2004)
`
`Rogawski MA, Diverse Mechanisms of Antiepileptic Drugs in the
`Development Pipeline, Epilepsy Res., Vol. 69(3), pg. 273 (2006)
`
`Statistical Review and Evaluation, Antiepileptic Drugs and
`Suicidality, U.S. Department of Health and Human Services, Food and
`Drug Administration, May 23, 2008
`
`Hardy BT et al., Double-Masked, Placebo-Controlled Study of
`Intravenous Levetiracetam for the Treatment of Status Epilepticus and
`Acute Repetitive Seizures in Dogs, J. Vet. Intern. Med., Vol. 26, pg.
`334 (2012)
`de Jong J et al., The Risk of Specific Congenital Anomalies in
`Relation to Newer Antiepileptic Drugs: A Literature Review,
`Drugs Real World Outcomes, Vol. 3(2), pg. 131 (2016)
`
`Silbergleit R et al., Intramuscular Versus Intravenous Therapy for
`Prehospital Status Epilepticus, The New England Journal of
`Medicine, Vol. 366(7), pg. 591 (2012)
`
`Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the
`Treatment of Super-Refractory Status Epilepticus (SRSE), Sage
`Therapeutics, https://clinicaltrials.gov/ct2/show/NCT02052739,
`Received January 28, 2014
`
`1
`
`
`
`
`
`
`
`
`
`1133
`
`1134
`
`1135
`
`1136
`
`1137
`
`1138
`
`1139
`
`1140
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Pinkhasov A et al., Lacosamide Induced Psychosis: Case Report,
`Review of Differential Diagnosis and Relevant Pharmacokinetics,
`Clin. Neuropharmacol., Vol. 38(5), pg. 198 (2015) (Abstract)
`
`Chatzistefanidis D et al., First Case of Lacosamide-Induced
`Psychosis, Clin. Neuropharmacol., Vol. 36(1), pg. 27 (2013)
`(Abstract)
`
`KEPPRA® (levetiracetam), Full Prescribing Information,
`www.keppraxr.com
`
`LYRICA® (pregabalin), Full Prescribing Information,
`www.accessdata.fda.gov
`
`TOPAMAX® (topiramate), Full Prescribing Information,
`www.accessdata.fda.gov
`
`DILANTIN® (Phenytoin Sodium 100 mg Extended Oral Capsule),
`Full Prescribing Information, www.accessdata.fda.gov
`
`LAMICTAL® (lamotrigine), Full Prescribing Information,
`www.accessdata.fda.gov
`
`Phenobarbital Sodium-phenobarbital sodium injection, Full
`Prescribing Information, West-ward Pharmaceutical Corp., www.
`dailymed.nlm.nih.gov
`
`1
`
`
`
`
`
`
`
`
`
`1141
`
`1142
`
`1143
`
`1144
`
`1145
`
`1146
`
`1147
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`NEURONTIN® (gabapentin), Full Prescribing Information,
`www.accessdata.fda.gov
`
`DEPAKOTE® (divalproex sodium), Full Prescribing Information,
`www.accessdata.fda.gov
`
`DEPAKENE® (valproic acid), Full Prescribing Information,
`www.accessdata.fda.gov
`
`TEGRETOL® (carbamazepine), Full Prescribing Information,
`www.accessdata.fda.gov
`
`Backonja M et al., Pharmacologic Management Part 1: Better-
`Studied Neuropathic Pain Diseases, Pain Medicine, Vol. 5(S1), pg.
`S28 (2004)
`
`Sadeghian H & Motiei-Langroudi R, Comparison of Levetiracetam
`and Sodium Valproate in Migraine Prophylaxis: A Randomized
`Placebo-Controlled Study, Ann. Indian Acad. Neurol., Vol. 18(1), pg.
`45 (2015)
`U.S. Subsidiary of Belgian Pharmaceutical Manufacturer Pleads
`Guilty to Off-Label Promotion; Company to Pay More Than $34
`Million: UCB Inc. Promoted Anti-Epileptic Drug Keppra for Off-
`Label Uses, FBI: Washington Field Office,
`https://archives.fbi.gov/archives/washingtondc/press-
`releases/2011/u.s.-subsidiary-of-belgian-pharmaceutical-
`manufacturer-pleads-guilty-to-off-label-promotion-company-to-pay-
`more-than-34-million (2011)
`
`1
`
`
`
`
`
`
`
`
`
`1148
`
`1149
`
`1150
`
`1151
`
`1152
`
`1153
`
`1154
`
`1155
`
`1156
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Novy J et al., Lacosamide Neurotoxicity Associated with Concomitant
`Use of Sodium Channel-Blocking Antiepileptic Drugs: A
`Pharmacodynamic Interaction?, Epilepsy & Behavior, Vol. 20, pg. 20
`(2011)
`Mete M et al., Effects of Lacosamide “A Novel Antiepileptic Drug” in
`the Early Stages of Chicken Embryo Development, Childs. Nerv.
`Syst., Vol. 32(9), pg. 1715 (2016)
`
`Sampath D et al., Characterization of Neonatal Seizures in an Animal
`Model of Hypoxic-Ischemic Encephalopathy, Epilepsia, Vol. 55(7),
`pg. 985 (2014)
`Chakravarthi S et al., Levetiracetam Versus Phenytoin in Management
`of Status Epilepticus, J. Clin. Neurosci., Vol. 22(6), pg. 959 (2015)
`
`Landmark J & Patsalos PN, Drug Interactions Involving the New
`Second-and Third-Generation Antiepileptic Drugs, Expert Rev.
`Neurother., Vol. 10(1), pg. 119 (2010)
`
`McCall C & McCall WV, What is the Role of Sedating
`Antidepressants, Antipsychotics, and Anticonvulsants in the
`Management of Insomnia?, Curr. Psychiatry Rep., Vol. 14(5), pg. 494
`(2012)
`Davis K et al., Glutamate Imaging (GluCEST) Lateralizes Epileptic
`Foci in Nonlesional Temporal Lobe Epilepsy, Science Translational
`Medicine, Vol. 7(309) (2015)
`
`Organic Chemistry, Racemic Mixtures, Enantiomeric Excess and
`Optical Purity (8th Edition) (L.G. Wade, Jr.)
`
`Transcript, Deposition of Dr. John Lehner (December 5, 2014), UCB,
`Inc., et al., v. Accord Healthcare, Inc., et al., No. 13-1206-LPS (D.
`Del., Nov. 9-13, 2015)
`
`1
`
`
`
`
`
`1157
`
`1158
`
`1159
`
`1160
`
`1161
`
`1162
`
`1163
`
`1164
`
`
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Abou-Khalil B, Levetiracetam in the Treatment of Epilepsy,
`Neuropsychiatric Disease and Treatment, Vol. 4(3), pg. 507 (2008)
`
`McDuff Declaration Attachment B-1 – D-2s
`
`Mayo Clinic, Epilepsy: Overview,
`http://www.mayoclinic.org/diseases-conditions/epilepsy/home/ovc-
`20117206.
`
`Epilepsy Foundation, About Epilepsy: The Basics,
`http://www.epilepsy.com/start-here/about-epilepsy-basics.
`
`Epilepsy Foundation, Seizure and Epilepsy Medicines,
`http://www.epilepsy.com/learn/treating-seizures-and-epilepsy/seizure-
`and-epilepsy-medicines.
`
`American Association for Clinical Chemistry Website, “Antiepileptic
`Drugs: Therapeutic Drug Monitoring of the Newer Generation
`Drugs,” 6/1/2013,
`https://www.aacc.org/publications/cln/articles/2013/june/antiepileptic-
`drugs.
`UCB, Annual Report, 2008.
`
`UCB, Annual Report, 2009.
`
`1
`
`
`
`
`
`1165
`
`
`1166
`
`1167
`
`1168
`
`1169
`
`1170
`
`1171
`
`1172
`
`
`
`
`
`UCB, Annual Report, 2014.
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`
`Vimpat (lacosamide) Label, 10/28/2008.
`
`Vimpat (lacosamide) Label, 8/29/2014.
`
`022255),
`(NDA
`Vimpat
`Details,
`Drug
`FDA,
`http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fusea
`ction=Search.DrugDetails.
`
`
`Letter from FDA to UCB, Re: “Supplement Approval,” 8/29/2014.
`
`November 13, 2015 Testimony of DeForest McDuff in UCB, Inc. et
`al. v. Accord Healthcare, Inc., et al., Case No. 13-1206-LPS (District
`of Delaware) (Excerpts).
`
`November 13, 2015 Trial Demonstratives from Testimony of
`DeForest McDuff in UCB, Inc. et al. v. Accord Healthcare, Inc., et al.,
`Case No. 13-1206-LPS (District of Delaware).
`
`Radley, David C., Stan N. Finkelstein, Randall S. Stafford (2006),
`"Off-label Prescribing Among Office-Based Physicians," Archives of
`Internal Medicine," 166(9): 1021-1026.
`
`1
`
`
`
`
`
`1173
`
`
`1174
`
`1175
`
`1176
`
`1177
`
`1178
`
`1179
`
`1180
`
`
`
`
`
`UCB Epilepsy Meetings, UCB: The Epilepsy Company,
`http://www.ucbepilepsymeetings.com/.
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`
`UCB, Annual Report, 2008, at 8, 49.
`
`UCB, Annual Report, 2009.
`
`Pfizer, Financial Report, 2005.
`
`Pfizer, Form 10-K - Financial Report, 2014.
`
`GlaxoSmithKline, Annual Report, 2007, at 37, 78.
`
`Johnson & Johnson, Annual Report, 2008.
`
`Mestre-Ferrandiz, Jorge, Jon Sussex, and Adrian Towse (2012), “The
`R&D Cost of a New Medicine,” Office of Health Economics, London
`UK, 1–86.
`
`1
`
`
`
`
`
`
`
`
`
`1181
`
`1182
`
`1183
`
`1184
`
`1185
`
`1186
`
`1187
`
`1188
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`DiMasi, Joseph, Henry Grabowski, and Ronald Hansen (2016),
`"Innovation in the pharmaceutical industry: New estimates of R&D
`costs," Journal of Health Economics 47: 20–33.
`
`DiMasi, Joseph, Henry Grabowski, and John Vernon (2004), “R&D
`Costs and Returns by Therapeutic Category,” Drug Information
`Journal 38: 211–223.
`
`Letter from FDA to UCB, Re: “NDA Approval”, 4/20/2010.
`
`David, Jesse and Marion B. Stewart (2005), “Commercial Success:
`Economic Principles Applied to Patent Litigation,” in Gregory K.
`Leonard and Lauren J. Stiroh, ed., Economic Approaches to
`Intellectual Property Policy, Litigation, and Management, White
`Plains, NY: National Economic Research Associates, Inc.
`
`Vimpat Clinical Trials,
`https://www.clinicaltrials.gov/ct2/show/NCT00220415?term=Vimpat
`&rcv_s=01%2F01%2F2000&rcv_e=01%2F01%2F2007&rank=11
`
`UCB, Clinical Study Information for Vimpat (lacosamide),
`http://www.ucb.com/rd/clinical-study-information/vimpat-lacosamide.
`
`Merck & Co., Inc. v. Teva Pharmaceuticals USA, Inc., 395 F.3d 1364,
`1376–77 (Fed. Cir. 2005).
`
`FDA Orange Book, 2014.
`
`1
`
`
`
`
`
`
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`Fischer, Marc, Peter S. H. Leeflang, and Peter C. Verhoef (2010),
`“Drivers of Peak Sales for Pharmaceutical Brands,” Quantitative
`Marketing and Economics 8(4): 429–460.
`
`Wazana, Ashley (2000), “Physicians and the Pharmaceutical
`Industry,” JAMA 283(3):373-380.
`
`Chren, Mary-Margaret, and Seth Landefeld (1994), “Physicians’
`Behavior and Their Interactions with Drug Companies,” JAMA
`271(9): 684-689.
`
`Schwartz, Thomas, and Daniel Kuhles, Michael Wade, and Prakash
`Masand (2001), “Newly Admitted Psychiatric Patient Prescriptions
`and Pharmaceutical Sales Visits,” Annals of Clinical Psychiatry 13(3):
`159-162.
`Gagnon, Marc-Andre and Joel Lexchin (2008), “The Cost of Pushing
`Pills: A New Estimate of Pharmaceutical Promotion Expenditures in
`the United States,” PLoS Med 5(1): 29-33.
`
`Pfizer Website, Dilantin Label,
`http://labeling.pfizer.com/showlabeling.aspx?id=544 (accessed
`5/26/2015).
`
`FDA Website, Tegretol Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016608s09
`8lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Depakote Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018723s03
`9lbl.pdf (accessed 5/26/2015).
`
`
`1189
`
`1190
`
`1191
`
`1192
`
`1193
`
`1194
`
`1195
`
`1196
`
`2
`
`
`
`
`
`
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`
`FDA Website, Depakote ER Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/18081s44,1
`8082s27,18723s33,19680s22,20593s15,21168s14lbl.pdf (accessed
`5/26/2015).
`
`FDA Website, Neurontin Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020235s04
`3lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Lamictal Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022251,020
`764s029,020241s036lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Lamictal XR Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022115s00
`6lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Topamax Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020505s03
`8s039,020844s032s034lbl.pdf (accessed 5/26/2015).
`
`Trokendi XR Website, Trokendi XR Label,
`http://www.trokendixr.com/hcp/pdfs/trokendi-prescribing-
`information.pdf (accessed 5/26/2015).
`
`FDA Website, Qudexy XR Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s00
`0lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Keppra Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s07
`8s080,021505s021s024lbl.pdf (accessed 5/26/2015).
`
`1197
`
`1198
`
`1199
`
`1200
`
`1201
`
`1202
`
`1203
`
`1204
`
`2
`
`
`
`
`
`
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`
`FDA Website, Keppra XR Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022285s00
`1lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Trileptal Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021014s02
`6,021285s021lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Zonegran Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020789s02
`2s025lbl.pdf (accessed 5/26/2015).
`
`Pfizer Website, Lyrica Label,
`http://labeling.pfizer.com/ShowLabeling.aspx?id=561#section-1
`(accessed 5/26/2015).
`
`FDA Website, Banzel label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021911s00
`5lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Sabril Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020427s00
`0lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Potiga Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s00
`0lbl.pdf (accessed 5/26/2015).
`
`FDA Website, Fycompa Label,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.p
`df (accessed 5/26/2015).
`
`1205
`
`1206
`
`1207
`
`1208
`
`1209
`
`1210
`
`1211
`
`1212
`
`2
`
`
`
`
`
`PETITIONER'S UPDATED EXHIBIT LIST
`IPR2016-00204
`U.S. National Library of Medicine Website, Aptiom Label,
`http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d0c9554-
`eaeb-4694-8089-00133fcadce3 (accessed 5/26/2015).
`
`1213
`
`Respectfully Submitted,
`
`Dated: November 14, 2016
`
`By:
`
`/Matthew J. Dowd/
`
`Matthew J. Dowd
`Reg. No. 47,534
`Dowd PLLC
`1717 Pennsylvania Avenue, NW
`Suite 1025
`Washington, D.C. 20006
`mjdowd@dowdpllc.com
`(202) 573-3853
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the above-captioned
`Petitioner’s Updated Exhibit List will be served on November 14, 2016 via e-mail
`to the attorney(s) of record for the patent at the addresses below:
`
`areister@cov.com
`jrobbins@cov.com
`rlongton@cov.com
`
`Covington & Burling LLP
`One City Center, 850 Tenth Street, NW
`Washington, DC 20001
`
`By:
`
`/Matthew J. Dowd/
`
`Matthew J. Dowd
`Reg. No. 47,534
`Dowd PLLC
`1717 Pennsylvania Avenue, NW
`Suite 1025
`Washington, D.C. 20006
`mjdowd@dowdpllc.com
`(202) 573-3853